How many investments has Iaso Ventures made?

Iaso Ventures has 32 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.

What stage does Iaso Ventures invest at?

Iaso Ventures invests at the Seed, Series A stages.

Where is Iaso Ventures located?

Iaso Ventures is headquartered in Cambridge, US.

Who does Iaso Ventures co-invest with?

Iaso Ventures most often shares deals with Virtue Ventures, BlueYard Capital, Civilization Ventures Management, Llc, among 59 tracked co-investors.

What size deals does Iaso Ventures back?

Across 6 deals with disclosed amounts, Iaso Ventures has joined rounds of $1M – $120M (median $17.5M).

Iaso Ventures

Venture capital

Cambridge · Seed–Series A · 15 people tracked

Also known as IASO VENTURES MANAGEMENT FIRM LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Iaso Ventures

4,541 people in our graph share verified history with the Iaso Ventures team — schools, employers, funds. One of them is your warm intro.

Yousuf Shehadiunlockedknows Sharon Tan · together at Garuda Therapeutics (overlapped)

knows the team · via Searle

knows the team · via Mass General Brigham Ventures

×2knows the team · via Dewpoint Therapeutics

knows the team · via Celera

knows the team · via Harvard Medical School and Massachusetts General Hospital

✨ Fox Verdict

Investment thesis

Iaso Ventures focuses on biodigital innovation at the intersection of life sciences and technology. The firm invests in game-changing startups aiming to cure disease and improve patient lives, backing data-driven enabling technologies and platforms that support next-generation therapeutic development. With an investor-operator DNA and a collaborative, industry-wide approach, the firm leverages deep sector expertise to accelerate growth and value creation. Its strategic partner network is positioned to provide an innovation ecosystem for portfolio companies.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Longevity Medical Devices Boston Cambridge United States

Source: firm website, verified Sep 27, 2026.

Stage

Seed–Series A

Cambridge, Massachusetts, US

Instruments

Equity

Founded

2019

Last 12 months

2 investments

Private fund assets

$37.5M

VC funds

Tracked investments

IPOs

Team · 15 people

from the firm's website & public directories

Wasim Q. Malik· Managing Partner· Boston, Massachusettsin

Managing Partner overseeing Iaso Ventures' strategy, investments and partnerships. Previously the first Chief Digital Strategist at Roivant Sciences, and a longtime research faculty member at Massachusetts General Hospital/Harvard Medical School and educator at MIT. Holds a DPhil in electrical engineering from Oxford, with postdoctoral neuroscience training at MIT and finance education from Harvard Business School.

w•••@iasoventures.comreveal

John Reynders· Chief Data Scientist & Venture Partner· Greater Bostonin

Chief Data Scientist and Venture Partner applying ML/AI and mathematical modeling to pharma/biotech decision support; also CTO of portfolio company Prudentia Sciences. Formerly held data science and information leadership roles at Neumora, Alexion, Moderna, AstraZeneca and Johnson & Johnson. Holds a PhD in applied and computational mathematics from Princeton and an MBA from Northwestern Kellogg.

Mark G. Currie· Venture Partner· Boston, Massachusetts, United Statesin

Venture Partner and veteran biopharma scientist and drug developer, known as primary inventor of linaclotide (Linzess) and former President/CSO and scientific founder of Cyclerion Therapeutics. Holds board and advisory roles across several biotech companies. Earned a PhD from Wake Forest School of Medicine.

Michael Fenn· Venture Partner· Boston, Massachusettsin 𝕏

Venture Partner sourcing deals and leading scientific and business due diligence; also Head of External Innovation at Dewpoint Therapeutics. Previously Director of Healthcare & Life Sciences at Harvard Innovation Labs and an assistant professor of biomedical engineering. Holds a PhD in Biomedical Engineering from the University of Florida.

Anil S. Jina· Executive in Residence· San Jose, California, United Statesin

Executive in Residence and physician with extensive biopharma experience across biotech, pharma, medical device and digital health. Held medical leadership roles at Pfizer, Sanofi, Shire and PPD, and served as Chief Medical Officer at Akili Interactive. Studied medicine at RCSI in Ireland.

Chandra Ramanathan· Advisor, Biotech· Cambridge, Massachusetts, United Statesin

Advisor on biotech covering drug discovery, drug delivery and biomanufacturing; VP and Head of External Innovation in the Life Sciences Innovation Group at Danaher. Previously Global Head of Pharma Open Innovation at Bayer with earlier roles at Wyeth and Bristol Myers Squibb. Holds a PhD in bioinformatics and genomics and an MBA from Columbia.

Maurizio Fava· Advisor, Clinical R&D· Boston, Massachusetts, United Statesin

Advisor on clinical R&D; Psychiatrist-in-Chief at Massachusetts General Hospital, executive director of the MGH Clinical Trials Network and Institute, and Slater Family Professor of Psychiatry at Harvard Medical School. A world leader in depression research and co-principal investigator of the STAR*D study.

Noah Richmond· Advisor, Legal & IP· San Francisco Bay Areain

Advisor on legal and IP; a technology attorney and business strategist with over 15 years building technology platforms. Held legal and regulatory leadership roles at Google, Motorola and Verily Life Sciences. Earned a PhD in Management Science and Engineering from Stanford and was the first graduate of Stanford's Bio-X Law and Bioengineering dual degree program.

Raymond Sanchez· Advisor, Drug Development

Advisor on drug development; a psychiatrist with 20+ years of experience and Senior Advisor at Bain Capital Life Sciences. Former Chief Medical Officer of Cerevel Therapeutics (acquired by AbbVie) and involved in developing compounds such as Abilify and Rexulti. Earned an MD from Northwestern's Feinberg Medical School and trained at Yale.

Sadiqa Mahmood· Entrepreneur in Residence· Boston, MA and Houston, TXin

Entrepreneur in Residence and physician focused on unmet needs across disease areas and technology-enabled therapeutic development. Recently SVP and GM of the Life Sciences business at Health Catalyst, with prior analytics and population health leadership at Dana-Farber, Mass General Brigham and Boston Medical Center. Holds a master's in public health from Harvard Chan School.

Sharon Tan· Executive in Residence· Boston, Massachusetts, United Statesin

Executive in Residence with over 20 years in clinical and preclinical development and pipeline strategy, focused on rare diseases and gene therapy. Held program leadership roles at Garuda Therapeutics, enGene, Ultragenyx and Sanofi Genzyme, including leading the FDA-approved Xenpozyme program.

Steve Schachter· Advisor, Medtech· Boston, Massachusetts, United Statesin

Advisor on medtech; Chief Academic Officer for CIMIT in Boston and Professor of Neurology at Harvard Medical School. Past President of the American Epilepsy Society, focused on accelerating medical technologies from bench to commercialization, including directing the NIH RADx Tech program.

Brian O'Connor· Executive Officer

Lambertus Johannes Hermanus Becht· Executive Officer

William R. Mordan· Executive Officer

What they invest in

from 25 of 32 portfolio companies

Biotech ×16Healthtech ×16Medical Devices ×10Digital Health ×9Deep Tech ×7AI & Machine Learning ×6Data & Infrastructure ×3SaaS ×3

HQs:United States×14Canada×1

Who they back

founder profiles across 14 portfolio companies

43%

solo founders

6 of 14 mapped founding teams

35%

repeat founders

of 17 founders with career history

Founding team size:solo founder×62 founders×63 founders×2

What their founders studiedfrom 15 founders with field-of-study data

Engineering ×6Life Sciences ×4Business & Management ×3Chemistry ×3Economics ×2Medicine ×2

Where their founders worked beforefrom 17 founders with career history

Harvard Medical School ×2Health Catalyst ×2UC Berkeley ×2

Accelerator rootsportfolio companies that came through a program

Y Combinator ×2

Investments · 32 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 1 2024 · 3 2023 · 2 2022 · 4 2021 · 113 dated

Certaracertara.com in 𝕏NASDAQ: CERTApr 2026SEC filingmedium confidence

Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases.

AI & Machine LearningBiotechHealthtechSaaSRadnor, US

Adrian McKemey(President, Certara Drug Development Solutions)in Rona Anhalt(Chief Human Resources Officer)in Daniel Corcoran(SVP and General Counsel)in Leif Pedersen(President, Chief Commercial Officer)in William Feehery(CEO and Director)in Jieun W. Choe(Chief Strategy & Marketing Officer)in

Board seat John Reynders· per SEC Form D · filed Apr 2026

Co-investorsArsenal

Aerskaaerska.com inFeb 2026 · $39M

Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.

BiotechDeep TechHealthtechMedical Devices

Stuart Milstein(Co-Founder)in Jack O’Meara(Cofounder)in

Co-investorsage1 Backed BlueYard Capital Entrepreneur First PsyMed Ventures Speedinvest +4 more

Axonis Therapeuticsaxonis.us inOct 2024

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)in Jeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in

Board Corey . Goodman(Director)in Jonathan Leff(Director)in

Co-investorsvenBio Partners MRL Ventures Fund Sofinnova Ventures Civilization Ventures Management, Llc Creative Destruction Lab (CDL)Hatteras Venture Partners +8 more

Beaconbeacon.bio

Beacon Biosignals develops AI-powered EEG analytics technology to improve diagnosis and treatment of neurological, psychiatric, and sleep disorders.

AI & Machine LearningBiotechDigital HealthMedical DevicesBoston, US

Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jacob A. Donoghue(Executive Officer, Director, Promoter)in Jacob Donoghue(CEO & Co-Founder)inJarrett Revels(CTO & Co-Founder)in

BoardCaitlin Donovan(Director)Pavel Raifeld(Director)

Co-investorsGeneral Catalyst Alumni Ventures Catalio Capital Management, LP GV (Google Ventures)Kicker Ventures Casdin Capital +3 more

Cadence Neurosciencecadenceneuro.com in

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.

BiotechDigital HealthHealthtechMedical DevicesSammamish, US

Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)

Co-investorsJAZZ Venture Partners Lumira Ventures Angelini Ventures F-Prime Capital Mayo Clinic Ventures

Catenacatena-nano.com in

The page is a blog post offering beginner tips for planning a first concrete pour, covering site preparation, forming, finishing, and curing.

Construction Tech

Co-investorsElevate Ventures QED Investors a16z crypto Acrew Capital Breyer Capital General Catalyst +6 more

Catena Biosciencescatenabio.com inSeed · Mar 2023 · $5M

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

Marco Lobba(Founder)inMatthew Francis(Founder)in Marco Lobba, Ph.D.(Founder)in

Co-investorsCALIFORNIA INNOVATION Civilization Ventures Management, Llc Creative Destruction Lab (CDL)FREEFLOW Jude Gomila LongeVC +6 more

Celericelerihealth.com

Celéri builds real-world evidence infrastructure that connects point-of-care outcomes, commercial registries, and regulatory-grade data for medtech and pharma sponsors, interventional pain physicians, and payers.

Digital HealthHealthtechMedical Devices

Co-investorsTwelve Below

Clexbioclexbio.comNov 2022 · $1M

Deep 6 AIdeep6.ai inSeries B · Jun 2022 · $30M

Data & InfrastructureHealthtechPasadena, US

Wout Brusselaers(Executive Officer, Director)in Sondra Pepe(Executive Officer)in Christian Duvall(Executive Officer)inAntonia Holway(Executive Officer)in Doug Cassidy(Executive Officer)in Peter Casasanto(Executive Officer)in

Co-investorsInformed Ventures Advisors, Llc MemorialCare Innovation Fund Point72 Ventures Techstars TMC Venture Fund GSR Ventures

Epiwatchepiwatch.com in

EpiWatch is an FDA-cleared seizure detection app for Apple Watch that monitors for tonic-clonic seizures and sends real-time alerts to users and their caregivers.

Digital HealthHealthtechMedical DevicesBaltimore, US

Nathan Crone(Executive Officer, Director, Promoter)Gregory Krauss(Executive Officer, Director, Promoter)Teresa Prego(Executive Officer, Director)inDean Papadopoulos(Executive Officer, Director, Promoter)

BoardDaniel Hanley(Director)Richard Schmitt(Director)

Co-investorsMaryland TEDCO TEDCO

Hexelonhexel.comDefunct

A platform that enables communities to launch their own cryptocurrencies.

ConsumerCrypto & Web3Travel & HospitalityNew York City, US

John Palmer(Founder/CEO)in

Co-investorsBlock54 Capital Valor Equity Partners Y Combinator

Inflection Medicineinflectionmedicine.com

Inflection Medicine offers a genomic medicine platform that integrates into the EHR to manage genomic sequencing and unify genomic, clinical, and family data into a single continuously updated patient view.

BiotechDigital HealthHealthtech

Mensura Healthmensurahealth.com

Mensura Health is developing an electrochemical point-of-care diagnostic system that uses DNA aptamer-based sensors and disposable microfluidic cartridges to rapidly measure blood levels of anti-seizure medications in epilepsy patients.

BiotechDigital HealthMedical DevicesWeston, US

Steven Schachter(Founder & Head Scientific Advisor)inNancy Hsiung(Founder & Chief Operating Officer)Charles Keough(Founder & Chief Executive Officer)Valentin Gribkoff(Executive Officer, Director)

BoardRobert Smith(Independent Director, Chairman of the Board)

Neumirna Therapeuticsneumirna.com

Neumirna develops miRNA-based therapies for neurological diseases such as epilepsy and Parkinson's.

BiotechLongevity

Co-investorsInvivo Capital Partners Sunstone Capital

Neurauraneuraura.com in 𝕏

Neuraura Biotech develops proprietary 3D micro-electrode and microsensor technology for high-fidelity neural recording and percutaneous stimulation, used to improve diagnostic and therapeutic solutions for neurological, psychiatric and sensory conditions.

BiotechFemTechHealthtechMedical DevicesCalgary, CA

Claire Dixon(CEO & Co-Founder)in Pierre Wijdenes(CPO & Co-Founder)in

Co-investorsStartup TNT BoxOne Ventures

Neurona Therapeuticsneuronatherapeutics.com inJul 2024 · $120M

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)in Catherine Priest(Chief Development Officer)in Gautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBerkeley Frontier The Column Group Ysios Capital Alexandria Fidelity Investments LYFE Capital +7 more

Prudentia Sciencesprudentiasciences.com in 𝕏

Prudentia Sciences provides information and evaluation services for biotech and pharmaceutical companies to help investors and acquirers assess breakthrough therapies before due diligence begins.

AI & Machine LearningBiotechEnterprise SoftwareHealthtech

Sadiqa Mahmood(CEO & Founder)in

Co-investorsGeneral Atlantic McKesson Ventures Virtue Ventures

Ryghtryght.ai inSeed · Aug 2023 · $4.3M

Ryght AI provides an artificial intelligence-powered platform that uses digital twin technology to help clinical research organizations and sponsors identify and select optimal sites for clinical trials.

AI & Machine LearningBiotechHealthtechMedical Devices

Dr. Chadi Nabhan(Chief Medical Officer)Tom Pike(President and Chief Executive Officer)

Co-investorsAIX Ventures Foothill Ventures Page One Ventures Virtue Ventures LDV Partners Top Harvest Capital

Scaffoldscaffoldtx.com

Scaffold Therapeutics is a biotech company developing oral small-molecule therapies that restore normal activity of the TDP-43 protein to treat ALS and other TDP-43-driven neurodegenerative diseases.

BiotechDeep TechHealthtech

Statcounterstatcounter.com in 𝕏

Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.

AdTechData & InfrastructureMarketing TechSaaS

Aodhán Cullen(Founder and CEO)

Co-investorsGabriel Venture Partners Homegrown Capital Huangpu River Capital Kumpulan Modal Perdana Nucleation Capital Nventure +2 more

Tuva Healthtuvahealth.com in

Tuva provides infrastructure and data standardization solutions for healthcare analytics teams, enabling them to transform raw healthcare data into analysis-ready datasets.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSSalt Lake City, US

Aaron Neiderhiser(Founder)in Coco Zuloaga(Founder)in

Co-investorsVirtue Ventures Y Combinator

Zafrenszafrens.com inDec 2021

Zafrens develops a unified drug discovery platform that integrates isolation, imaging, and sequencing workflows to accelerate the identification of therapeutic compounds across modalities.

AI & Machine LearningBiotechDeep TechSan Diego, US

Martin Smrcina inMaina Ndunguin Swamy Vijayan(Executive Officer, Director)in Yi Zhang in Vikas Goel in

Board Justin Briggs in

Co-investorsAcequia Capital (AceCap)BlueYard Capital Global Brain HAWKTAIL imec.xpand Raptor Group +2 more

Zenith Healthzenithhealth.ioPre-Seed · Aug 2024

Zenith was a women's health company offering an app and an AI assistant called Penny to support women through pregnancy with information and guidance.

Digital HealthFemTechHealthtech

Zeto Inczeto-inc.com in 𝕏

Zeto develops improved electroencephalography technology for diagnosing epilepsy and other neurological conditions.

Cloud ComputingDeep TechDigital HealthHealthtechMedical DevicesSan Francisco, US

Aswin Gunasekar(Founder and CEO)in

Co-investorsAphelion Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Sea PharmaceuticalsAurelisBeacon BiosignalsHexokine TherapeuticsPragma BioScaffold TherapeuticsSoovu

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 1

1 IPOs

CertaraNASDAQ: CERT

Portfolio news

latest coverage across their companies

Axios: Ryght AI raises seed to shrink clinical trial timelines

Ryght · ryght.ai · Jul 28, 2025

Frequently asked questions

How many investments has Iaso Ventures made?: Iaso Ventures has 32 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.
What stage does Iaso Ventures invest at?: Iaso Ventures invests at the Seed, Series A stages.
What sectors does Iaso Ventures focus on?: Iaso Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Iaso Ventures located?: Iaso Ventures is headquartered in Cambridge, US.
Who does Iaso Ventures co-invest with?: Iaso Ventures most often shares deals with Virtue Ventures, BlueYard Capital, Civilization Ventures Management, Llc, among 59 tracked co-investors.
What size deals does Iaso Ventures back?: Across 6 deals with disclosed amounts, Iaso Ventures has joined rounds of $1M – $120M (median $17.5M).

Co-investors · 1

Pioneer

Pioneer Fund is a venture capital firm investing in the top Y Combinator startups.

Firms observed investing alongside Iaso Ventures, from public investor directories. Shared companies are the overlap with Iaso Ventures's recorded portfolio.

Similar investors

Future Positive Capital

Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.

$5K – $50M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.

$100K – $4M

Artis Ventures

ARTIS Ventures is a venture capital firm investing in breakthrough companies at the convergence of technology and biology, with a focus on healthcare and life sciences ('TechBio'). It backs founders across biotech, therapeutics, digital health, and frontier technologies.

$50K – $25M